The VDPHL01 medication has demonstrated successful outcomes in treating hair loss during late-stage clinical trials. According to reports, this pill has effectively promoted hair growth in men experiencing mild to moderate alopecia without causing serious side effects. VDPHL01 employs a specialized formulation of minoxidil with extended release properties, allowing for a gradual release of the active ingredient over an extended period.
Veradermics, the company behind VDPHL01, intends to announce the results of another phase of research later this year. Following this, the final testing and submission for FDA approval will commence.
